Eli Lilly & Co. (NYSE:LLY) had its price target upped by JPMorgan Cazenove from $57.00 to $59.00 in a research note issued to investors on Thursday, Analyst Ratings.Net reports. The firm currently has a neutral rating on the stock.
A number of other analysts have also recently weighed in on LLY. Analysts at Barclays Capital raised their price target on shares of Eli Lilly & Co. from $55.00 to $58.00 in a research note to investors on Thursday. They now have an equal weight rating on the stock. Separately, analysts at Zacks reiterated a neutral rating on shares of Eli Lilly & Co. in a research note to investors on Thursday. They now have a $55.00 price target on the stock. Finally, analysts at UBS AG raised their price target on shares of Eli Lilly & Co. to $52.00 in a research note to investors on Thursday. They now have a buy rating on the stock.
One analyst has rated the stock with a sell rating, nine have given a hold rating and ten have assigned a buy rating to the stock. Eli Lilly & Co. presently has an average rating of Hold and a consensus price target of $56.19.
Shares of Eli Lilly & Co. (NYSE: LLY) traded up 0.36% during mid-day trading on Thursday, hitting $53.55. Eli Lilly & Co. has a 52 week low of $42.10 and a 52 week high of $58.40. The stock’s 50-day moving average is currently $51.07. The company has a market cap of $58.050 billion and a P/E ratio of 11.99.
The company also recently declared a quarterly dividend, which is scheduled for Tuesday, September 10th. Shareholders of record on Thursday, August 15th will be given a dividend of $0.49 per share. This represents a $1.96 dividend on an annualized basis and a yield of 3.67%. The ex-dividend date of this dividend is Tuesday, August 13th.
Eli Lilly and Company discovers, develops, manufactures, and sells products, in one business segment, pharmaceutical products.